AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17044763 — intervention group
Group type: EXPERIMENTAL
Intervention: TTM-based expert system intervention
Number of subjects: 1227
Study 14554075 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing with Sensodyne
Number of subjects: 50
Study 14554075 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing with Emoform
Number of subjects: 50
Study 14554075 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing with Sorriso
Number of subjects: 50
Study 14554075 — intervention group
Group type: COMPARATOR
Intervention: No brushing
Number of subjects: 50
Study 14554075 — intervention group
Group type: COMPARATOR
Intervention: Brushing without dentifrice
Number of subjects: 50
Study 11003347 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ganciclovir (2 g t.i.d. for 2 weeks, then 1 g t.i.d. for 4 weeks)
Number of subjects: 72
Study 11003347 — intervention group
Group type: COMPARATOR
Intervention: i.v. ganciclovir (5 mg/kg q 12 hr for 7 days)
Number of subjects: 72
Study 11003347 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ganciclovir
Number of subjects: 72
Study 11003347 — intervention group
Group type: COMPARATOR
Intervention: No antiviral prophylaxis (for patients without CMV antigenemia)
Number of subjects: 72
Study 8794491 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg d-amphetamine
Number of subjects: 9
Study 8794491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 1736831 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT-M (UFT, Mitomycin C)
Number of subjects: 62
Study 1736831 — intervention group
Group type: COMPARATOR
Intervention: UFT-D (UFT, Doxorubicin)
Number of subjects: 62
Study 6146425 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 14
Study 6146425 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 14
Study 6146425 — intervention group
Group type: COMPARATOR
Intervention: Propranolol after Nadolol
Number of subjects: 14
Study 6146425 — intervention group
Group type: COMPARATOR
Intervention: Nadolol after Propranolol
Number of subjects: 14
Study 3536889 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 74
Study 3536889 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 74
Study 3536889 — intervention group
Group type: COMPARATOR
Intervention: Trazodone
Number of subjects: 74
Study 30239667 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved urban environment (IUE) with coaching (C+)
Number of subjects: 52
Study 30239667 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved urban environment (IUE) without coaching (C-)
Number of subjects: 52
Study 30239667 — intervention group
Group type: COMPARATOR
Intervention: Control group (WIUE) with coaching (C+)
Number of subjects: 52
Study 30239667 — intervention group
Group type: COMPARATOR
Intervention: Control group (WIUE) without coaching (C-)
Number of subjects: 52
Study 26727410 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-Belief techniques
Number of subjects: 59
Study 26727410 — intervention group
Group type: EXPERIMENTAL
Intervention: CT techniques (directive CT techniques - CT-Concrete)
Number of subjects: 59
Study 24100751 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper endoscopy first
Number of subjects: 163
Study 24100751 — intervention group
Group type: COMPARATOR
Intervention: Colonoscopy first
Number of subjects: 163
Study 23988908 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice containing 1.5% arginine and 1,450 ppm fluoride
Number of subjects: 6000
Study 23988908 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice containing insoluble calcium compound and 1,450 ppm fluoride
Number of subjects: 6000
Study 23988908 — intervention group
Group type: COMPARATOR
Intervention: Control dentifrice containing 1,450 ppm fluoride
Number of subjects: 6000
Study 20573923 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional doses of inactivated poliovirus vaccine (0.1 ml, intradermally)
Number of subjects: 400
Study 20573923 — intervention group
Group type: COMPARATOR
Intervention: Full doses of inactivated poliovirus vaccine (intramuscularly)
Number of subjects: 400
Study 20573923 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional doses of inactivated poliovirus vaccine
Number of subjects: 400
Study 20573923 — intervention group
Group type: COMPARATOR
Intervention: Full doses of inactivated poliovirus vaccine
Number of subjects: 400
Study 20573923 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 400
Study 18769864 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral levetiracetam (LEV) 500 mg twice daily
Number of subjects: 3
Study 18769864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 16835214 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate 150 mg daily
Number of subjects: 33
Study 16835214 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 33
Study 14693303 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg, titrated to 160 mg if poorly controlled; added hydrochlorothiazide (HCTZ) 12.5 mg if needed after 16 weeks.
Number of subjects: 421
Study 14693303 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 5 mg, titrated to 10 mg if poorly controlled; added hydrochlorothiazide (HCTZ) 12.5 mg if needed after 16 weeks.
Number of subjects: 421
Study 10867446 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrifonate 60/80 mg
Number of subjects: 2016
Study 10867446 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrifonate 30-60 mg
Number of subjects: 2016
Study 10867446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2016
Study 8657520 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 26
Study 8657520 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 26
Study 1889243 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity, symptom-limited, endurance exercise training
Number of subjects: 52
Study 6357936 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg, acute administration)
Number of subjects: 13
Study 6357936 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (chronic administration, dosage reducing heart rate by 25%)
Number of subjects: 13
Study 6357936 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (acute and chronic administration)
Number of subjects: 13
Study 30289371 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 105
Study 30289371 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 105
Study 30289371 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 30289371 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 105
Study 30232865 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with rehabilitation exercise
Number of subjects: 196
Study 30232865 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation exercise (control group)
Number of subjects: 196
Study 26626336 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (n=10) performing barbell back squats and deadlifts twice per week for four weeks
Number of subjects: 22
Study 26626336 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=12)
Number of subjects: 22
Study 24462241 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivationally-enhanced viral hepatitis education and counseling intervention
Number of subjects: 440
Study 24462241 — intervention group
Group type: COMPARATOR
Intervention: Standard counseling (Control)
Number of subjects: 440
Study 22595353 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraventricular urokinase (Uk)
Number of subjects: 0
Study 22595353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19903658 — intervention group
Group type: EXPERIMENTAL
Intervention: AA plus G (Nutrineal 1.1% plus Physioneal 1.36% to 3.86%)
Number of subjects: 12
Study 19903658 — intervention group
Group type: COMPARATOR
Intervention: G only (control dialysate)
Number of subjects: 12
Study 18572233 — intervention group
Group type: COMPARATOR
Intervention: Physical Activity (PA) intervention with bupropion and nicotine patch, including a pedometer, counseling to increase steps by 10% biweekly towards a 10,000 steps/day goal, and personalized reports for 40 weeks.
Number of subjects: 407
Study 18572233 — intervention group
Group type: COMPARATOR
Intervention: Physical Activity (PA) intervention with bupropion and nicotine patch.
Number of subjects: 407
Study 16032913 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted video instruction (customized set of exercises downloaded from a computerized database)
Number of subjects: 40
Study 16032913 — intervention group
Group type: COMPARATOR
Intervention: Routine rehabilitation practice (traditional group received routine inpatient rehabilitation exercise education from physical therapists)
Number of subjects: 40
Study 11581563 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resistance (HR) training, 3 times per week at 80% maximum strength (1RM)
Number of subjects: 36
Study 11581563 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable-resistance (VR) training, 3 times per week at 80%, 65%, and 50% 1RM
Number of subjects: 36
Study 11581563 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 36
Study 9532686 — intervention group
Group type: EXPERIMENTAL
Intervention: Hep-A-in-Vac vaccine
Number of subjects: 14000
Study 7976448 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimozide
Number of subjects: 66
Study 7976448 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 66
Study 7976448 — intervention group
Group type: COMPARATOR
Intervention: Medication-free clinical treatment
Number of subjects: 66
Study 2563389 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment
Number of subjects: 53
Study 2563389 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic treatment
Number of subjects: 53
Study 799992 — intervention group
Group type: EXPERIMENTAL
Intervention: Floctafenine
Number of subjects: 312
Study 799992 — intervention group
Group type: COMPARATOR
Intervention: Pentazocine
Number of subjects: 312
Study 799992 — intervention group
Group type: COMPARATOR
Intervention: Dihydrocodeine
Number of subjects: 312
Study 799992 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 312
Study 799992 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 312
Study 31022252 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive treatments for RA (e.g., non-biologic drugs like hydroxychloroquine, atorvastatin, biologics)
Number of subjects: 288
Study 31022252 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral treatment vs. infusion
Number of subjects: 288
Study 31022252 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing reduction in risk of RA
Number of subjects: 288
Study 31022252 — intervention group
Group type: EXPERIMENTAL
Intervention: Health care professional preference
Number of subjects: 288
Study 31022252 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoiding irreversible serious side effects
Number of subjects: 288
Study 31022252 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoiding reversible serious side effects
Number of subjects: 288
Study 30573748 — intervention group
Group type: EXPERIMENTAL
Intervention: Licensed trivalent influenza vaccine
Number of subjects: 0
Study 30573748 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel virus-like particle based vaccine
Number of subjects: 0
Study 30573748 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 26986471 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent screening and treatment (ISTp) with dihydroartemisinin-piperaquine (DP)
Number of subjects: 36
Study 26986471 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment (IPTp) with dihydroartemisinin-piperaquine (DP)
Number of subjects: 36
Study 26986471 — intervention group
Group type: COMPARATOR
Intervention: Intermittent preventive treatment (IPTp) with sulphadoxine-pyrimethamine (SP)
Number of subjects: 36
Study 25210017 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous oral lenalidomide (20 mg/day)
Number of subjects: 45
Study 22691399 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (teacher-focused intervention)
Number of subjects: 1158
Study 22691399 — intervention group
Group type: COMPARATOR
Intervention: Delayed-treatment control group
Number of subjects: 1158
Study 19050386 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronate (5 mg intravenous)
Number of subjects: 30
Study 19050386 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 17515448 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine 18 mg
Number of subjects: 21
Study 17515448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 15223527 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-session groupwork for HIV prevention
Number of subjects: 50
Study 11600352 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference capsule formulation of amoxicillin
Number of subjects: 48
Study 11600352 — intervention group
Group type: EXPERIMENTAL
Intervention: Test capsule formulation of amoxicillin
Number of subjects: 48
Study 11600352 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference and test suspensions of amoxicillin
Number of subjects: 48
Study 11600352 — intervention group
Group type: EXPERIMENTAL
Intervention: Various amoxicillin formulations (250 to 1,000 mg)
Number of subjects: 48
Study 11600352 — intervention group
Group type: COMPARATOR
Intervention: LSS-derived AUC(0-infinity) and C(max)
Number of subjects: 48
Study 11600352 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-point LSS models for T>MICs of 0.25 or 2.0 microg/ml
Number of subjects: 48
Study 9425650 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom‐/NCS‐ hands
Number of subjects: 27
Study 9425650 — intervention group
Group type: COMPARATOR
Intervention: NCS‐ hands
Number of subjects: 27
Study 9425650 — intervention group
Group type: EXPERIMENTAL
Intervention: NCS+ hands
Number of subjects: 27
Study 9425650 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratio of the change in pinch rate with respect to required pinch force
Number of subjects: 27
Study 9425650 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinch rate
Number of subjects: 27
Study 9425650 — intervention group
Group type: EXPERIMENTAL
Intervention: Gap detection threshold and the ratio of the change in pinch rate with respect to required pinch force
Number of subjects: 27
Study 7584262 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptual cues (fragment cues)
Number of subjects: 0
Study 7584262 — intervention group
Group type: EXPERIMENTAL
Intervention: Conceptual cues
Number of subjects: 0
Study 7584262 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognition
Number of subjects: 0
Study 7584262 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit retrieval
Number of subjects: 0
Study 3120487 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg selegiline (1‐deprenyl)
Number of subjects: 15
Study 3120487 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg Madopar + 10 mg selegiline (1‐deprenyl)
Number of subjects: 15
Study 3120487 — intervention group
Group type: COMPARATOR
Intervention: 200 mg Madopar + placebo
Number of subjects: 15
Study 31351189 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 200 mg
Number of subjects: 1902
Study 31351189 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg
Number of subjects: 1902
Study 31351189 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 200 mg/300 mg
Number of subjects: 1902
Study 30563816 — intervention group
Group type: EXPERIMENTAL
Intervention: Education session by pharmacists (60 minutes)
Number of subjects: 72
Study 30563816 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 72
Study 27310616 — intervention group
Group type: EXPERIMENTAL
Intervention: Training of family physicians (FPs) to diagnose MCI and dementia (intervention component 1)
Number of subjects: 647
Study 27310616 — intervention group
Group type: EXPERIMENTAL
Intervention: Case finding of MCI and dementia and care by a trained nurse and the FP (intervention component 2)
Number of subjects: 647
Study 27310616 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control)
Number of subjects: 647
Study 27310616 — intervention group
Group type: COMPARATOR
Intervention: Mental health assessment among consenting participants in trial stage 2
Number of subjects: 647
Study 24758510 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional flow reserve guidance
Number of subjects: 0
Study 24758510 — intervention group
Group type: COMPARATOR
Intervention: Optical coherence tomography guidance
Number of subjects: 0
Study 24758510 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 0
Study 23575810 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (3.0 g/d)
Number of subjects: 186
Study 23575810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study 19912207 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine combined with behavioral therapies including individualized fluid management instructions
Number of subjects: 0
Study 19912207 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine alone
Number of subjects: 0
Study 19912207 — intervention group
Group type: EXPERIMENTAL
Intervention: General fluid management instructions
Number of subjects: 0
Study 18240033 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime history of suicide attempt
Number of subjects: 1245
Study 16316699 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary risk factors and inflammation assessment in CAD patients with ICD implants
Number of subjects: 110
Study 16316699 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cholesterol and LDL cholesterol levels
Number of subjects: 110
Study 16316699 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-CRP levels
Number of subjects: 110
Study 12746013 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive use
Number of subjects: 30
Study 12746013 — intervention group
Group type: COMPARATOR
Intervention: Normally menstruating
Number of subjects: 30
Study 12746013 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 10982759 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief psychodynamic‐interpersonal (PI) psychotherapy
Number of subjects: 95
Study 10982759 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy (control)
Number of subjects: 95
Study 8993956 — intervention group
Group type: EXPERIMENTAL
Intervention: Homoeopathic therapy (n = 30)
Number of subjects: 60
Study 8993956 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy (n = 30)
Number of subjects: 60
Study 7703597 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nutrition (IVN) for 10 days
Number of subjects: 7
Study 3316118 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (500 IU/day)
Number of subjects: 69
Study 3316118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 30653863 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (exercise group)
Number of subjects: 67
Study 30653863 — intervention group
Group type: COMPARATOR
Intervention: Inactive sedentary group (control group)
Number of subjects: 67
Study 28433443 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP) injections
Number of subjects: 101
Study 28433443 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopic lateral release
Number of subjects: 101
Study 23875573 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent pitches in an identification task
Number of subjects: 0
Study 23875573 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrequent pitches presented in isolation
Number of subjects: 0
Study 22134392 — intervention group
Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring (HBPM)
Number of subjects: 136
Study 22134392 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 136
Study 20658802 — intervention group
Group type: EXPERIMENTAL
Intervention: Nia (culturally informed, empowerment‐focused psychoeducational group intervention)
Number of subjects: 208
Study 20658802 — intervention group
Group type: EXPERIMENTAL
Intervention: Nia
Number of subjects: 208
Study 20658802 — intervention group
Group type: COMPARATOR
Intervention: TAU (treatment as usual)
Number of subjects: 208
Study 17587720 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (400 mg/day) 2 months before PTMV
Number of subjects: 23
Study 17587720 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (200 mg/day) after cardioversion
Number of subjects: 23
Study 17587720 — intervention group
Group type: EXPERIMENTAL
Intervention: PTMV
Number of subjects: 23
Study 15961764 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha-2a plus 13-CRA
Number of subjects: 320
Study 15961764 — intervention group
Group type: COMPARATOR
Intervention: IFN-alpha-2a alone
Number of subjects: 320
Study 11948889 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradient Field Transform (GFT)
Number of subjects: 125
Study 11948889 — intervention group
Group type: COMPARATOR
Intervention: Minimal Cost Algorithm (MCA)
Number of subjects: 125
Study 9579811 — intervention group
Group type: EXPERIMENTAL
Intervention: PGI/MN II monoclonal antibodies
Number of subjects: 142
Study 9579811 — intervention group
Group type: COMPARATOR
Intervention: D8/17 monoclonal antibodies
Number of subjects: 142
Study 7607786 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-ASA at 2.4 g/day in a delayed-release formulation (Eudragit-S-coated Mesaline)
Number of subjects: 66
Study 7607786 — intervention group
Group type: COMPARATOR
Intervention: Non-specific therapy (Control group)
Number of subjects: 66
Study 3049227 — intervention group
Group type: EXPERIMENTAL
Intervention: Linkage analysis using various selection rules on pedigree subsets
Number of subjects: 0
Study 3049227 — intervention group
Group type: EXPERIMENTAL
Intervention: Selection of recessive-appearing pedigrees for linkage analysis
Number of subjects: 0
Study 3049227 — intervention group
Group type: EXPERIMENTAL
Intervention: Including information on unaffected second-degree relatives in linkage studies
Number of subjects: 0